Cargando…

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent kinase, CDK1. This was discovered using parallel siRNA screens in KRAS mutant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J., Ashworth, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755568/ https://www.ncbi.nlm.nih.gov/pubmed/26881434 http://dx.doi.org/10.1371/journal.pone.0149099

Ejemplares similares

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
por: Yang, Zhang, et al.
Publicado: (2022)

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer
por: Brough, Rachel, et al.
Publicado: (2018)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

Mapping the Synthetic Dosage Lethality Network of CDK1/CDC28
por: Zimmermann, Christine, et al.
Publicado: (2017)

miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer
por: Palma, Francesco, et al.
Publicado: (2020)

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
por: Houles, Thibault, et al.
Publicado: (2022)

A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers
por: Mondal, Gourish, et al.
Publicado: (2019)

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
por: Conti, Annalisa, et al.
Publicado: (2015)

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
por: Padhye, Aparna, et al.
Publicado: (2021)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Metabolic plasticity in synthetic lethal mutants: Viability at higher cost
por: Massucci, Francesco Alessandro, et al.
Publicado: (2018)

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
por: Unni, Arun M, et al.
Publicado: (2015)

Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines
por: Okada, Yoshinari, et al.
Publicado: (2017)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Dual inhibition of CDK4 and FYN leads to selective cell death in KRAS-mutant colorectal cancer
por: Wang, Yan, et al.
Publicado: (2019)

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
por: Brägelmann, Johannes, et al.
Publicado: (2017)

Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens
por: Christodoulou, Eleni G., et al.
Publicado: (2017)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers
por: Kelso, Timothy W R, et al.
Publicado: (2017)

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
por: Lee, Michael S., et al.
Publicado: (2016)

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
por: Steckel, Michael, et al.
Publicado: (2012)

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
por: Xue, Yibo, et al.
Publicado: (2019)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Synthetic Vulnerabilities in the KRAS Pathway
por: Roman, Marta, et al.
Publicado: (2022)

A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells
por: Weïwer, Michel, et al.
Publicado: (2012)

Inhibiting glutamine utilization creates a synthetic lethality for suppression of ATP citrate lyase in KRas-driven cancer cells
por: Hatipoglu, Ahmet, et al.
Publicado: (2022)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS
por: Narvaez, Ana J., et al.
Publicado: (2017)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1e5232g7vccakmlgtthb0j53p3